We recognise that being diagnosed with cancer can be a devastating experience and that that you need regular, ongoing support during this time of your life. By registering with our Oncology Benefit Programme, we offer you and your healthcare provider access to oncology benefits and support from the outset of your treatment up to and including one year into your remission.

Why register with the Oncology Benefit Programme?

We have a dedicated team of Clinical Advisers and Case Managers, who are available to discuss, review and approve funding for your Oncology treatment together with your doctor or specialist.

As a result, we will pay for appropriate, evidence-based oncology medication and treatment, including associated treatment without co-payments. Payment is also based on your available benefits and your health insurance Policy Conditions.

By registering with the Oncology Benefit Programme, your qualifying claims will be paid from the Oncology Benefit, ensuring that your Day-to-day benefits will last longer.

Evidence-based treatment takes into account the results of trusted international clinical studies, side effects and cost-effectiveness of a medicine or treatment. We also rely on internationally accepted clinical guidelines from institutions such as the World Health Organisation (WHO) to guide our funding decisions.

If you have been diagnosed with cancer, please apply for enrolment on the Programme as soon as possible, as registration is not automatic.

How to register with the Oncology Benefit Programme

If you are diagnosed with any cancerous condition, together with your doctor or specialist, please complete and submit our Oncology application form to your in-country office or to the email address below. Please attach the histology report (laboratory results confirming the cancer diagnosis) to the application form.
Download Oncology Application Form

Once you are registered on the Programme, you will receive access to:

  • Chemotherapy and medicine directly associated with the treatment of your cancer, subject to benefit limits and policy conditions
  • Radiotherapy
  • Specialised radiology
    • CT/MRI scans (2 per insured person per annum)
    • PET scans (1 per insured person per annum) for staging purposes only
    • Bone scans (1 per insured person per annum)
  • Additional benefits to cover pathology, consultations and basic radiology
  • Palliative or supportive care – i.e. any treatment to manage your cancer symptoms, and improve your quality of life.

Please update us on changes to your treatment

  • You and your doctor or specialist need to update us on any changes to your treatment. This will help to ensure that your related claims are paid from the appropriate and available benefits.
  • Please see our contact details below.

Is there any treatment where funding is limited or excluded?

Our Oncology Benefit provides cover for most types of treatment. However, the medicines that are starred in the list below are limited to certain types of cancer and or lines of therapy, while the other medicines in the list are excluded from cover.

We may require additional clinical information or motivation for approval of the medicines that are starred.

Generic name

Trade name

  • Abiraterone
  • Zytiga®
  • Bendamustine
  • Ribomustin®
  • Bevacizumab
  • Avastin®
  • Bortezomib**
  • Velcade®, Valtib® and other biosimilars
  • Brentuximab
  • Adcetris®
  • Cabazitaxel
  • Jevtana®
  • Decitabine
  • Dacogen®
  • Enzalutamide
  • Xtandi®
  • Eribulin
  • Halaven®
  • Erlotinib**
  • Tarceva®
  • Everolimus**
  • Afinitor®
  • Imatinib**
  • Gleevec®
  • Ipilimumab
  • Yervoy®
  • Ixabepilone
  • Ixempra®
  • Nivolumab
  • Opdivo®
  • Panitumumab
  • Vectibix®
  • Pazopanib
  • Votrient®
  • Pembrolizumab
  • Keytruda®
  • Pemetrexed**
  • Alimta®
  • Pertuzumab
  • Perjeta®
  • Radium-223
  • Xofigo®
  • Regorafenib
  • Stivarga®
  • Rituximab**
  • Mabthera®
  • Ruxolitinib
  • Jakavi®
  • Sorafenib
  • Nexavar®
  • Sunitinib**
  • Sutent®
  • Temsirolimus
  • Torisel®
  • Trabectedin
  • Yondelis®
  • Trastuzumab**
  • Herceptin®, Ogivri® and other biosimilars
  • Trastuzumab emtansine
  • Kadcyla®
  • Vemurafenib
  • Zelboraf®
  • Vismodegib
  • Erivedge®

Trastuzumab – Herceptin® and biosimilars: we support funding for 6 months of therapy in early HER2 positive breast cancer.

Contact Us
(8 am – 5 pm weekdays, excl. public holidays)

+266 223 14590

[email protected]